RxDoctor Payments DataLook up a doctor →

Matthew Paul, MD

Ophthalmology · Danbury, CTNPI 1417955865

Payments from drug & device makers

$943,779in general payments, 2019–2025

Across 285 payments — averaging $3311.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$601K
  • Bausch Health US, LLC$163K
  • Genentech, Inc.$53K
  • Shire North American Group Inc$41K
  • Oyster Point Pharma, Inc.$22K
  • Perrigo Company PLC$19K
  • plus $45K from 17 others
$2,746in research payments, 2019–2025

Across 15 payments — averaging $183.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$943,779 in reported general payments places this provider in the 95th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$291,190
Medicare patients
861
Services billed
2,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →